← FDA DRUG APPROVALS

FDA ANDA · ANDA090585

ORPHENADRINE CITRATE

Sponsor: SAGENT PHARMS

APPLICATION
ANDA090585
TYPE
ANDA
ORIGINAL APPROVAL
2011-08-30
LATEST ACTION
2011-08-30
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ORPHENADRINE CITRATEPrescription
ORPHENADRINE CITRATE 30MG/ML · INJECTABLE · INJECTION

Approval history

2011-08-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →